Valentina Zuco
University of Milan
Downregulation and upregulationDNA damageTopoisomeraseChemistryApoptosisIn vivoRetinoidHistone deacetylaseCamptothecinCell cycleProgrammed cell deathCancer researchBiochemistryCell growthStereochemistryMedicineProtein kinase BCell cultureBiologyPharmacology
Publications 77
#1Silvia MartiniH-Index: 3
#2Valentina ZucoH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 10 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-proliferative activity induced by selinexor and miR-34a expression, singly and in combination, was evaluated by MTS assay and cell counting. The effect of treatments on survivin and apoptosis-related protein...
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard fron...
#1Rihan El BezawyH-Index: 3
#2Martina Tripari (University of Liverpool)H-Index: 1
Last. Nadia ZaffaroniH-Index: 66
view all 12 authors...
Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) is the most commonly mutated gene in prostate cancer (PCa). Recent evidence reports a role of SPOP in DNA damage response (DDR), indicating a possible impact of SPOP deregulation on PCa radiosensitivity. This study aimed to define the role of SPOP deregulation (by gene mutation or knockdown) as a radiosensitizing factor in PCa preclinical models. To express WT or mutant (Y87N, K129E and F133V) SPOP, DU145 and PC-3 cells were tra...
1 CitationsSource
#1Federica RotundoH-Index: 2
#2Denis CominettiH-Index: 14
Last. Paolo GandelliniH-Index: 25
view all 10 authors...
The development of novel therapies or the improvement of currently used approaches to treat prostate cancer (PCa), the most frequently diagnosed male tumor in developed countries, is an urgent need. In this regard, the functional characterization of microRNAs, molecules shown to regulate a number of cancer-related pathways, is instrumental to their possible clinical exploitation. Here, we demonstrate the tumor-suppressive role of the so far uncharacterized miR-1272, which we found to be signific...
1 CitationsSource
#1Silvia StacchiottiH-Index: 61
#2Valentina ZucoH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 21 authors...
Epithelioid sarcoma (ES) is a rare mesenchymal malignancy marked by SMARCB1/INI1 deficiency. Retrospective clinical data report on the activity of anthracycline- and gemcitabine-based regimens. EZH2 inhibitors are currently being tested in clinical trials. Since comparisons of these agents are unlikely to be prospectively evaluated in the clinics, we took advantage of an INI1-deficient proximal-type ES patient-derived xenograft (PDX ES-1) to comparatively assess its preclinical antitumor activit...
6 CitationsSource
Background Radiotherapy is one of the main treatment options for non-metastatic prostate cancer (PCa). Although treatment technical optimization has greatly improved local tumor control, a considerable fraction of patients still experience relapse due to the development of resistance. Radioresistance is a complex and still poorly understood phenomenon involving the deregulation of a variety of signaling pathways as a consequence of several genetic and epigenetic abnormalities. In this context, c...
28 CitationsSource
#1Noemi ArrighettiH-Index: 11
#2Claudia Corbo (Brigham and Women's Hospital)H-Index: 23
Last. Ennio Tasciotti (Houston Methodist Hospital)H-Index: 39
view all 6 authors...
: Cancer treatment still represents a formidable challenge, despite substantial advancements in available therapies being made over the past decade. One major issue is poor therapeutic efficacy due to lack of specificity and low bioavailability. The progress of nanotechnology and the development of a variety of nanoplatforms have had a significant impact in improving the therapeutic outcome of chemotherapeutics. Nanoparticles can overcome various biological barriers and localize at tumor site, w...
23 CitationsSource
#1Nadia ZaffaroniH-Index: 66
#2Anna Maria FrezzaH-Index: 16
Last. Silvia StacchiottiH-Index: 61
view all 14 authors...
11578Background: ES is a rare soft tissue sarcoma with two variants, i.e., the proximal and the distal. Retrospective data on the activity of anthracycline- and G-based regimens are available. EZH2...
#1N. BediniH-Index: 5
#2Alessandro Cicchetti (UNIPV: University of Pavia)H-Index: 7
Last. Riccardo Valdagni (University of Milan)H-Index: 51
view all 16 authors...
A recent “hot topic” in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a...
7 CitationsSource